Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy.
Acta Oncol
; 43(1): 15-9, 2004.
Article
in En
| MEDLINE
| ID: mdl-15068315
ABSTRACT
Paclitaxel is a new agent for advanced non-small cell lung cancer (NSCLC). Weekly doses may enhance antitumor activity while minimizing toxicity, but little is known about immune recovery. Paclitaxel (80 mg/m2) was administered to 10 patients with NSCLC, weekly during 3-week cycles. Natural killer (NK) activity, CD3-CD16+CD56+ NK cells, and differential counts were monitored. NK activity appeared in all patients after treatment with paclitaxel therapy NK activity showed a 27 +/- 9% decrease (mean +/- SE) on protocol day 8 and a 37 +/- 7% decrease on day 15 (p < 0.05) recovering to 89 +/- 5% of baseline on day 29. With weekly paclitaxel, a decrease in NK cell function persisted through the first cycle but then recovered. Weekly paclitaxel may be less immunosuppressive than agents such as cisplatin.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Paclitaxel
/
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Type of study:
Etiology_studies
/
Guideline
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Acta Oncol
Journal subject:
NEOPLASIAS
Year:
2004
Document type:
Article
Affiliation country: